Regeneron posts $5.1 billion Q3 revenue, beating forecasts and highlighting strong sales of Dupixent, Eylea HD and Libtayo

Regeneron reported third‑quarter revenue of $5.1 billion, well above the consensus range of $4.61‑$4.65 billion and representing a 36% increase from the same period last year.

The company attributed the growth to record net sales of its Sanofi‑partnered inflammatory drug Dupixent, the high‑dose eye treatment Eylea HD, and the cancer immunotherapy Libtayo.

Management expressed confidence in its disease‑agnostic pipeline and business development approach, noting that the strong commercial performance helped lift the stock more than 11% in early trading.

Analysts at RBC and BMO described the quarter as a clean sweep, pointing to beats across the board and an improving outlook for future sales.